TEVA was recommended by Top Stock Insights at $46.62 in Investment Digest issue 694, dated May 4, 2011. TEVA closed yesterday at $43.44.
“With the market extended, now is a great time to rake profits and eliminate positions that aren’t working. ... We closed our position in Teva Pharmaceutical Industries Ltd. (TEVA) this morning. [The company is] great, but [the stock hasn’t] done particularly well despite a broad-based rally. ... Teva has suffered in part due to weakness in Europe, but it’s also just not the growth story it once was.
“I still like the healthcare sector and will likely add more exposure to it in the Top Stock Insights portfolio later this year.”
- Ian Wyatt, Top Stock Insights, March 15, 2012